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The  prototype  dioxin  congener  2,3,7,8-tetrachlorodibenzo-p-dioxin  (TCDD)  is  known  to
exert anti-estrogenic  effects  via  activation  of the  aryl  hydrocarbon  receptor  (AhR)  by
interfering  with  the  regulation  of  oestrogen  homeostasis  and  the  estrogen  receptor  
(ER) signalling  pathway.  The  AhR/ER  cross-talk  is  considered  to play  a crucial  role  in
TCDD-  and  E2-dependent  mechanisms  of carcinogenesis,  though  the  concerted  mecha-
nism  of action  in  the liver  is not  yet elucidated.  The  present  study  investigated  TCDD’s
impact  on  the  transcriptional  cross-talk  between  AhR  and  ER  and its modulation  by
17-estradiol  (E2)  in  the human  hepatoma  cell  line  HepG2,  which  is AhR-responsive  but
ER-negative.  Transient  transfection  assays  with  co-transfection  of  hER  and supplemen-
tation  of receptor  antagonists  showed  anti-estrogenic  action  of TCDD  via  down-regulation
of  E2-induced  ER signaling.  In contrast,  enhancement  of AhR signaling  dependent  on  ER
was  observed  providing  evidence  for  increased  cytochrome  P450 (CYP)  induction  to  pro-
mote E2 metabolism.  However,  relative  mRNA  levels  of  major E2-metabolizing  CYP1A1ene reporter assay and  1B1  and  the main  E2-detoxifying  catechol-O-methyltransferase  were  not  affected  by
the co-treatments.  This study  provides  new  evidence  of  a TCDD-activated  AhR-mediated
molecular  AhR/ER  cross-talk  mechanism  at transcriptional  level  via  indirect  inhibition  of
ER  and  enhanced  transcriptional  activity  of  AhR  in HepG2  cells.
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1. Introduction
The prototype dioxin congener 2,3,7,8-tetrach-
lorodibenzo-p-dioxin (TCDD) is a highly toxic and
persistent organic pollutant, which is ubiquitously found
in  the environment. There is extensive evidence in vivo
and  in vitro that TCDD exerts anti-estrogenic effects via
activation of the arylhydrocarbon receptor (AhR) by inter-
fering  with the regulation of estrogen homeostasis and the
estrogen  receptor  (ER) signaling pathway (reviewed in
[1]).  A number of mechanisms were proposed to describe
dioxin-mediated AhR/ER cross-talk ([2,3]).
is is an open access article under the CC BY-NC-ND license
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It was hypothesized that TCDD may  interfere with the
regulation of estrogen homeostasis resulting in reduced
concentrations of circulating estrogens. This is thought
to  result from enhanced oxidative metabolism of 17-
estradiol (E2) via AhR-mediated induction of cytochromes
P450 (CYPs), particularly CYP1A1 and CYP1B1 [4]. The latter
also  serve as general surrogate markers for AhR activation
[5].
Furthermore, TCDD may  also prevent binding of the
E2/ER-complex to the estrogen response element (ERE)
and  instead recruit the hormone receptor to AhR target
genes via an indirect protein-protein interaction [6,7]. It
was  shown that E2-dependent expression of genes and
proteins such as pS2, cathepsin D and vitellogenin were
inhibited by the action of TCDD [8]. Furthermore, TCDD
was  reported to inhibit E2-induced cell proliferation and
DNA  synthesis by speciﬁcally blocking the E2-induced
transition from G1 to S phase [9]. TCDD also induced
the degradation of ER through activation of the protea-
some as observed in breast cancer cell lines [10] and it
mediated the down-regulation of ER levels via a repres-
sor  site in the promoter region of ER-regulated genes [3].
Most  of these studies were performed using breast can-
cer  cell lines or other hormone-related cells and focused
on  AhR agonists which directly affected ER-dependent
pathways [11–13]. In contrast, TCDD did not show direct
activation of ER in a competitive binding assay [14].
TCDD has been classiﬁed as a human carcinogen by the
International Agency for Research on Cancer [15], its car-
cinogenic effect in rodent liver being most probably related
to  its mode of action as a liver tumour promoter [5]. AhR
signaling-dependent suppression of apoptosis of preneo-
plastic hepatocytes seems to play a central role in this effect
[16].
Interestingly, TCDD was found to be a more potent
liver carcinogen in female rats compared to male rats and
it  reduced age-related spontaneous hormone-dependent
tumours, suggesting a role of estrogens [17,18]. Exposure
to  E2 is primarily associated with increased risk of breast
cancer [19]. However, E2 was also related to liver carcino-
genesis and it has been postulated to promote ER-mediated
growth stimulation via co-mitogenic effects [20]. In rat pri-
mary  hepatocytes in culture a co-mitogenic action of TCDD
and  estrogens was reported [21].
Altogether, the AhR/ER cross-talk is considered to play
a  crucial role in TCDD- and E2-dependent mechanisms
of liver carcinogenesis, though the exact mechanism of
action  in the liver is not yet elucidated. Furthermore, the
metabolism of estrogens via CYPs primarily occurs in the
liver  [4]. In this study TCDD’s impact on the transcriptio-
nal cross-talk between AhR and ER and its modulation
by E2 was investigated in the human hepatoma cell line
HepG2, which is AhR responsive but deﬁcient for ER [22].
Transient transfection assays were performed using the
luciferase gene regulated by either the ERE or the dioxin
response element (XRE) with or without co-transfection of
a  human ER expression vector. Furthermore, differential
mRNA expression of major E2-metabolizing CYPs and the
main  E2-detoxifying gene catechol-O-methyltransferase
(COMT) was assessed in the presence or absence of
ER.rts 1 (2014) 1029–1036
2.  Materials and methods
2.1.  Cell culture and treatments
The  human hepatoma cell line HepG2 (European Col-
lection of Cell Cultures, ECACC No 85011430) was  grown
in  phenol red-free Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% foetal bovine serum
(FBS), 1% penicillin/streptomycin, and 4 mM l-glutamine
(cell culture media and supplementations were obtained
from PAA Laboratories) maintained at 37 ◦C and 5% CO2.
Cells  were seeded in culture medium with 10% FBS (or 10%
dextran-coated charcoal treated FBS (DCC-FBS) for trans-
fection  assays) for 24 h. HepG2 cells were either placed
on  60 mm-diameter plates (0.375 × 106 cells/mL) for RNA
extraction or on 24 well-plates (0.12 × 106 cells/mL) for
transfection assays and RNA extraction from transfected
cells. Cells were treated with TCDD 1 nM (Promochem)
and/or E2 10 nM (Sigma–Aldrich) dissolved in dimethyl
sulfoxide (DMSO, max. 0.25%; Sigma–Aldrich) in com-
plete phenol red-free DMEM with 0.5% FBS (or without
FBS for transfection assays). Additionally, simultaneous
treatments with the AhR antagonist -naphthoﬂavone (-
NF,  Sigma–Aldrich) or the pure anti-estrogen ZK 191 703
(kindly  provided by Dr. Karl-Heinrich Fritzemeier, Bayer-
Schering, Germany) were performed.
2.2. Transient transfection
HepG2  cells were transiently transfected with XRE-
or  ERE-dependent luminescent reporter genes (ERE-TK-
Luc  or XRE-Luc) using ExGen 500 transfection agent
(Euromedex) and co-transfected or not with a hER expres-
sion  vector. Plasmids pCMV-Gal and pSG5 served as
control plasmids (kindly supplied by Dr. M.  Cherkaoui-
Malki, LBMN, University of Burgundy, Dijon, France).
Plasmids ERE-TK-Luc and pRST7-hER were kindly pro-
vided  by Dr. D. McDonnell (Ligand Pharmaceutical, San
Diego,  USA). The reporter gene plasmid pGL3-XRE-Luc was
previously  described [23,24].
Transient transfections were performed following man-
ufacturer’s instructions. Brieﬂy, plasmid mixes were
prepared as follows: 100 ng ERE-TK-Luc or XRE-Luc, 100 ng
hER,  100 ng of pCMV and pSG5 to a ﬁnal concentra-
tion of 0.5 g DNA. For transfections omitting hER, the
amount of pSG5 was adjusted accordingly. The Exgen
500/DNA mixture was added to appropriate amounts of
phenol  red-free Opti-MEM (Invitrogen) and transferred to
the  wells. After transfection medium was removed and
replaced by fresh DMEM medium (without DCC-FBS) con-
taining  test substances or the solvent control. E2 10 nM
and  TCDD 1 nM served as the positive controls for ERE- or
XRE-mediated luciferase activity, respectively. After 20 h
treatment  cells were lysed with Reporter Lysis Buffer 1×
(Promega). The microplate was  then frozen at −80 ◦C for
at  least 30 min. Cells were scraped off, transferred into
microtubes, and submitted to three sequential freezing-
thawing cycles in liquid nitrogen and at 37 ◦C. Microtubes
were centrifuged (5 min, 10,000 × g, room temperature)
and 10 L of the lysate were pipetted into an opaque white
96-well plate. A volume of 50 L luciferase assay reagent
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Table 1
Sequences of primers and ﬂuorogenic probes used for ampliﬁcation of
mRNA gene products in Real-time RT PCR.
Gene Primer sequence (5′–3′)
hCYP1B1 Sense:  GCT AAA CCC GCT GTC CAT CC
Anti-sense: CCG CCT CCG TTG CCT CAG
Probe: 6-FAM-ACC ACG CTC CTG CTA CTC CTG TCG
G-TAMRA
hCYP1A1 Sense:  CCT CTT TGG AGC TGG GTT TG
Anti-sense: CCT GTG GGG GAT GGT GAA
h36B4 Sense:  ACT TGC TGA AAA GGT CAA GG
Anti-sense: TTC CTT GGC TTC AAC CTT AG
hAhR Sense:  TCC ACA GTT GGC TTT GTT TGC
Anti-sense: TGT GAA GTC CAG TTT GTG TTT GG
Probe: 6-FAM-CTA CTC CAC TTC AGC CAC CGT
CCATCCT-TAMRA
hER Sense: AAG ATC AAC GAC ACT TTG ATC CAC
Anti-sense: ATG CCT TTG TTA CTC ATG TGC C
Probe: 6-FAM-CTG GCC CAG CTC CTC CTC ATC
CT-TAMRA
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chCOMT Sense: ACA GTG CTA CTG GCT GGC TGA CAA
Anti-sense: GGC TGT CTT GGA ACT CAC TT
Promega) was added to each well, the plate covered with
n  adhesive seal and immediately read in a microplate
uminometer (TopCountNT, Packard). The -galactosidase
ctivity was determined using chlorophenol-red -d-
alactopyranoside (CPRG) (Roche), and the chlorophenol
ed product was measured on a microplate spectropho-
ometer at 570 nm (MRX Dynex). Protein levels were
easured on a spectrophotometer at 595 nm (MRX Dynex)
ccording to the Bradford method [25]. Luciferase activ-
ty  was normalized against -galactosidase activity and
rotein contents and related to the respective positive con-
rols.
.3.  RNA extraction and real-time RT PCR
Total RNA was isolated with the RNeasy Mini Kit
Qiagen). Samples were quantiﬁed spectrophotometri-
ally via a NanoDrop 1000 Spectrophotometer (Thermo
isher Scientiﬁc). RNA (0.5 g) was reverse-transcribed
nto cDNA using the iScript cDNA Synthesis Kit (Bio-
ad) following DNase treatment (Desoxyribonuclease I,
mpliﬁcation Grade, Invitrogen). Real-time PCR was  per-
ormed  in a total volume of 25 L per reaction on an
Cycler iQ Real-Time PCR Detection System with iCycler
oftware version 3.1 (Bio-Rad). Each PCR reaction con-
ained  25 ng of the diluted cDNA, 12.5 L of AbsoluteTM
PCR SYBR® Green Fluorescein Mix  (Thermo Fisher Sci-
ntiﬁc), 200 nM of forward and reverse primers and pure
ater  (qsp 25 l). When a ﬂuorogenic probe was used
PCR Master Mix  no ROX (Eurogentec, Belgium) with a
rimer  mix  containing the primer pairs (300 nM/well) and
he  ﬂuorogenic probe (100 nM/well) were added instead.
rimer sets were designed using the free software primer
 (http://frodo.wi.mit.edu/) and purchased from MWG.
luorogenic probes were designed and obtained from Euro-
entec  (primer sequences see Table 1). Optimized PCR
onsisted of 45 cycles at 95 ◦C for 15 s followed by ampliﬁ-
ation at 58–60 ◦C for 30 or 60 s. For real-time PCR usingrts 1 (2014) 1029–1036 1031
SYBR Green mix, a melting curve emerging in a gradi-
ent starting at the respective annealing temperature up
to  90 ◦C in increasing steps of 0.5 ◦C veriﬁed the single
PCR product. Expression of the target gene relative to the
estradiol-independent 36B4 reference gene [26] normal-
ized  to the solvent control was  calculated using the Ct
comparative method [27].
2.4. Statistical analysis
Experiments  were performed at least in triplicates.
Results are presented as mean ± SD. The One-way ANOVA
followed by Tukey’s post test was performed to analyze the
reporter  gene data. For the statistical analysis of the gene
expression data the Two-way ANOVA followed by the Bon-
ferroni  post test was  applied. For graphs and statistics the
software GraphPad Prism 5 for Windows was used.
3.  Results
3.1. Effects off ER  ˛ on ERE-and XRE-dependent
transcriptional activity
HepG2  were transiently co-transfected with ERE-TK-
LUC and the hER expression vector. E2 (10 nM)  resulted
in  a signiﬁcant induction of reporter gene activity. TCDD
(1  nM)  signiﬁcantly decreased E2-induced ERE-mediated
activity by about 50%, whereas TCDD alone had no effect on
ERE-mediated transcription (Fig. 1). The partial AhR antag-
onist  -naphthoﬂavone reversed TCDD’s anti-estrogenic
action and the pure estrogen antagonist ZK 191 703 com-
pletely  blocked the estrogenic action of E2.
In cells lacking the transfected ER none of the tested
compounds had any effect on reporter gene expression
(data not shown). In the same way, XRE-luc reporter was
co-transfected or not with hER into HepG2 cells (Fig. 2).
E2  (10 nM)  signiﬁcantly enhanced TCDD-induced AhR-
regulated transcription up to 1.6-fold in co-transfected
cells, whereas E2 alone had no effect on transcriptional
activity via the AhR. By adding the anti-estrogen ZK 191
703,  this enhancement by the co-treatment was  abolished,
while the XRE-driven increase by TCDD was still observed.
The  AhR-mediated action of TCDD was partially inhibited
by  the AhR antagonist -naphthoﬂavone, while addition
of  E2 to TCDD/-naphthoﬂavone further enhanced this
inhibitory effect. Application of the anti-oestrogen ZK 191
703  or experiments with XRE-luc without exogenous ER
reversed  the potentiating effect by E2. In any case basal lev-
els  of reporter plasmid (ERE or XRE)-mediated activity were
not  inﬂuenced by transfection of ER or solvent treatment.
3.2. Relative expression of major E2-metabolizing CYPs
and  detoxifying COMT after treatment with TCDD and/or
E2  in the presence and absence of ER˛
Receptor transcript levels for ER and AhR were not
changed with treatments (Fig. 3). With regard to rela-
tive  CYP expression (normalized to respective controls)
there was no difference in response to TCDD between
non-transfected and ER-transfected HepG2 cells. TCDD
(1  nM)  induced both CYP1A1 and CYP1B1 mRNA, whereas
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Fig. 1. Effects of ER on ER-mediated transcription. HepG2 cells were transiently transfected with ERE-TK-LUC and co-transfected with human ER
expression  plasmid as described in Section 2. Cells were treated with TCDD and/or E2 over a period of 20 h. An induction equal to 100% was attributed to
 as a pe
Tukey’s 
treatmethe  luciferase activity of treatment with E2 and all results were expressed
to  111,133 ± 7564 cps). Mean ± SD (n ≥ 3); One-way ANOVA followed by 
***p  ≤ 0.0001; signiﬁcant difference between respective E2 and E2/TCDD 
the latter response was less pronounced. E2 alone had no
impact  on CYP1A1 and CYP1B1 mRNA compared with sol-
vent  control. Furthermore, E2 showed no modulating effect
on  TCDD-induced CYP expression.
The treatments had no signiﬁcant inﬂuence on COMT
mRNA levels (Fig. 3). However, transcript levels were
signiﬁcantly different in the TCDD treatment and the co-
treatment with and without ER transfection.
4. Discussion
4.1. Relevance of AhR/ER cross-talk for the liver
In this study a well-known in vitro human liver can-
cer cell model, the HepG2 hepatoma cell line, was  used to
investigate the mode of action of the cross-talk between
ER and AhR following treatment with E2 and/or TCDD.
Transient transfection assay responses and mRNA analysis
conﬁrmed HepG2 cell line to be AhR-responsive. However,
cells  were ER deﬁcient, which is in accordance with Iwa-
nari  et al. [22]. Thus, to analyze receptor interaction in
detail,  the study was performed in hER overexpressed
HepG2 cells after transient transfection.Though for some less potent AhR agonists such as 3-
methylcholanthrene a direct activation of ER resulted
in  an estrogenic response, TCDD has been reported to
be  an indirect ER inhibitor and exert anti-estrogenicrcentage of the luciferase activity of this positive control (corresponding
post test: signiﬁcantly different from solvent control (DMSO 0.2% max.):
nts as indicated; n.s.: not signiﬁcant.
effects [6,11–14]. Previous studies on the AhR/ER cross-talk
mainly focused on investigating these effects in breast can-
cer  cell lines. However, the liver is one of the major target
organs of TCDD’s toxic action mediated via AhR. Thus, the
focus  of this research work was put on the liver since the
liver  is also one major site of estradiol metabolism and the
ER  is highly expressed [28].
4.2. AhR/ER cross-talk: TCDD’s anti-estrogenic action on
transcriptional activity of ER
In HepG2 cells TCDD led to anti-estrogenic activity by
reducing E2-mediated ER signalling in the ERE-regulated
reporter gene activity assay only in the presence of ER.
The  complete ER antagonist ZK 191 703 totally blocked
the  estrogenic response and application of the partial AhR
antagonist -naphthoﬂavone [29] reversed TCDD’s anti-
estrogenic repression of AhR-dependent reporter gene
activity in HepG2 cells. Thus, these results support the
hypothesis that the ligand-activated AhR interacts with
ER  and represses E2-bound ER-mediated transcription
upon ERE similarly to what is reported in hormone-
dependent cell lines [6,7,30]. The activation of AhR by
TCDD  is supposed to be a crucial step in the interac-
tion of AhR/ER, since various experiments in AHR-deﬁcient
cell models have failed to demonstrate the modulation
of ER functional activity. In multiple ER-positive breast
M. Göttel et al. / Toxicology Reports 1 (2014) 1029–1036 1033
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Fig. 2. Effects of ER on AhR-mediated transcription. HepG2 cells were transiently transfected with pGL3-XRE and co-transfected or not with human ER
expression  plasmid as described in Section 2. Cells were treated with TCDD and/or E2 over a period of 20 h. An induction equal to 100% was attributed to the
luciferase  activity of treatment with TCDD in ER-transfected cells and all results were expressed as a percentage of the luciferase activity of this positive
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ontrol  (DMSO 0.2% max.): *p ≤ 0.01, **p ≤ 0.001, ***p ≤ 0.0001; signiﬁcant
ot  signiﬁcant.
nd endometrial cancer cells TCDD was shown to be
trongly anti-estrogenic, such as in MCF-7 breast cancer
ells,  but also in ER-negative Hepa-1 mouse hepatoma cells
ransfected  with an ER expression vector [3,10,30–32].
n contrast, in a non-functional AhR mutant Hepa-1 cell
ine  TCDD failed to exert an effect on E2-dependent ER
ignalling, suggesting an interaction between AhR and ER
athways  [30]. Similarly, the expression of E2-responsive
enes/proteins and their related activities was decreased
n  multiple ER-positive breast and endometrial cancer cells
fter  co-treatment of E2 and TCDD and the identiﬁcation of
o-called  inhibitory XREs (iXREs) in the critical promoter
egions of these E2-responsive genes provided further evi-
ence  for the inhibition of E2-dependent target genes via
nteraction with the activated AhR [3,31–35].
.3. AhR/ER cross-talk: E2-enhanced transcriptional
ctivity of AhR
Reciprocally, HepG2 cells transiently transfected with
 XRE-luc reporter showed enhanced TCDD-mediated
uciferase activity upon E2 treatment only in the pres-
nce  of constitutively over-expressed ER. TCDD alone
esulted in increased luciferase activity independent of
he  ER. Thus, E2-activated ER is suggested to interact
ith XRE-bound AhR, playing a role in the enhance-
ent of AhR signalling. One proposed mechanism of theNOVA followed by Tukey’s post test: signiﬁcantly different from solvent
nce between respective TCDD and E2/TCDD treatments as indicated; n.s.:
AhR/ER  cross-talk is the enhanced metabolism of E2 by
CYPs,  particularly CYP1A1 and 1B1, which are induced
by the potent AhR ligand TCDD [3]. Our data are consis-
tent with reports in other cell lines showing a positive
effect of ER on the modulation of AHR-responsiveness
[36–38]. The repression of TCDD-induced luciferase activ-
ity  by the AhR antagonist -naphthoﬂavone suggests a
partial  inhibition which was however further inhibited
in  the presence of E2, suggesting an enhancement of the
antagonist effect by the co-treatment. Data from Matthews
and  co-workers in ER- and AhR-positive MCF-7 and T47D
human  breast cancer cells revealed that TCDD (10 nM)-
bound AhR recruited ER to the CYP1A1 and CYP1B1
promoters [7]. This promoter occupancy was enhanced by
additional  treatment with E2 (10 nM). Studies with the
AhR-responsive HuH7 human hepatoma cell line lacking
ER  revealed that increasing amounts of ER expres-
sion resulted in a concentration-dependent potentiation of
TCDD-induced XRE-driven luciferase reporter gene activity
after  24 h co-treatment of TCDD with E2 1 nM and 10 nM
[7,39].
4.4.  Impact of AHR/ER cross-talk on AhR-responsive gene
expression
In  a recent study stable siRNA-mediated knockdown
of ER in non-tumorigenic HC11 mouse mammary
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Fig. 3. Real-time RT PCR analysis of ER, AhR, CYP1A1, CYP1B1, and COMT mRNA in non-transfected and ER-transfected HepG2. Effects of TCDD 1 nM
and/or  E2 10 nM were assayed after 20 h exposure. Mean ± SD (n ≥ 3); Two-way ANOVA followed by the Bonferroni post test: statistically signiﬁcant
from  respective transfected or untransfected solvent control (DMSO 0.25%): *p ≤ 0.05, ∗∗∗p ≤ 0.001; signiﬁcant difference between respective treatment of
transfected  and non-transfected cells: $p ≤ 0.05; n.d.: not detected.
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pithelial cells revealed reduced TCDD-induced CYP1A1
RNA expression [40]. Despite the increasing effects of
CDD-induced CYP1A1 luciferase activity by E2 in ER-
ransfected HepG2 cells neither TCDD-induced CYP1A1 nor
YP1B1  mRNA levels were affected by the co-treatments
pon ER transfection in the present study. This result is
n  apparent contradiction to the XRE-driven reporter gene
ata  and may  be due to the large degree of CYP induction
hich may  activate signalling pathways limiting the over-
ll  response or due to the higher sensitivity of the luciferase
ssay. Alternatively, the ER-dependent added interaction
ith AhR may  be target gene-dependent which requires
urther clariﬁcation.
.5.  Impact of AHR/ER cross-talk on COMT gene
xpression
In addition to the CYPs, COMT was investigated in
epG2 since changes in its expression may  be a limiting
actor in the balance of estradiol metabolism. COMT is the
ajor  E2 detoxifying enzyme, which catalyses inactivation
f  the two main reactive catechol estradiol metabolites
41]. In HepG2 cells TCDD alone and the co-treatment
lightly increased COMT mRNA in the presence of ER
ompared to controls. An estrogenic down regulation of
uman  COMT requiring the presence of ERs was  previ-
usly described. It has been reported that E2 reduced
OMT transcription in ER-positive MCF-7 cells but not in
R-negative HeLA cells [42]. In the AhR-positive but ER-
egative human breast cancer cell line MCF-10F, under
onditions in which E2 metabolism has been enhanced by
CDD,  increased levels of catechol estrogens and depuri-
ating DNA adducts were detected in the presence of a
OMT  inhibitor, suggesting the balance of COMT activity
s  an important factor in cancer initiation [43].
. Conclusion
A  complex AhR/ER cross-talk at the transcriptio-
al level was demonstrated in the human hepatoma
ell line HepG2 applying speciﬁcally designed transient
ransfection assays with co-transfection of hER and the
upplementation of antagonists of both the ER and AhR
eceptors. TCDD demonstrated an anti-estrogenic action
ia  down-regulation of the E2-mediated induced ER-
ignalling. This anti-estrogenic action is supposed to occur
ia  an indirect activation of ER since TCDD alone had no
ffect  on ER-dependent transcriptional activity. At the
ame  time enhanced AhR activation was observed depend-
nt  on ER resulting in enhanced XRE-driven reporter gene
xpression but not in enhanced expression of the AhR
arget  genes CYP1A1 and 1B1. Thus, concomitant effects
f  TCDD and E2 resulted in anti-estrogenic activity and
n  enhancement of certain but not all AhR-dependent
ranscriptional activities. This study provides further evi-
ence  that AhR/ER cross-talk can play a crucial role in
he  regulation of estrogen-mediated and TCDD-related
echanism of action in the liver. Different responses
n HepG2 cells compared to cells derived from mainly
ormone-regulated tissues may  indicate that the involved
olecular mechanisms of the ER and AhR signaling differ in
[rts 1 (2014) 1029–1036 1035
cell-  or tissue-dependent manner such as receptor levels or
available  co-regulatory proteins that may  interact with the
receptors.
Overall,  HepG2 cell line is an appropriate tool to fur-
ther elucidate the molecular mechanisms in the liver
which are involved in the nuclear receptor interactions.
The mechanism of estrogen receptor signaling alteration
by  TCDD-activated AhR is important to understand the
estrogen-related adverse effects of TCDD on the liver as one
of  its target organs.
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